EAU Guidelines on Renal Cell Carcinoma: 2014 Update

Abstract

Context: The European Association of Urology Guideline Panel for Renal Cell Carcinoma (RCC) has prepared evidence-based guidelines and recommendations for RCC management. Objectives: To provide an update of the 2010 RCC guideline based on a standardised methodology that is robust, transparent, reproducible, and reliable. Evidence acquisition: For the 2014 update, the panel prioritised the following topics: percutaneous biopsy of renal masses, treatment of localised RCC (including surgical and nonsurgical management), lymph node dissection, management of venous thrombus, systemic therapy, and local treatment of metastases, for which evidence synthesis was undertaken based on systematic reviews adhering to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Relevant databases (Medline, Cochrane Library, trial registries, conference proceedings) were searched (January 2000 to November 2013) including randomised controlled trials (RCTs) and retrospective or controlled studies with a comparator arm. Risk of bias (RoB) assessment and qualitative and quantitative synthesis of the evidence were performed. The remaining sections of the document were updated following a structured literature assessment. Evidence synthesis: All chapters of the RCC guideline were updated. For the various systematic reviews, the search identified a total of 10 862 articles. A total of 151 studies reporting on 78 792 patients were eligible for inclusion; where applicable, data from RCTs were included and meta-analyses were performed. For RCTs, there was low RoB across studies; however, clinical and methodological heterogeneity prevented data pooling for most studies. The majority of studies included were retrospective with matched or unmatched cohorts based on single or multi-institutional data or national registries. The exception was for systemic treatment of metastatic RCC, in which several RCTs have been performed, resulting in recommendations based on higher levels of evidence.

Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer

“…The current standard of care is cytoreductive nephrectomy followed by vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) 1 . The use of nephrectomy in metastatic disease was established prior to the development of VEGF TKIs 2,3 .…”

The relationship between renal warm ischemia time and glomerular loss. An experimental study in a pig model

“…Thus, partial nephrectomy is considered the gold standard for treating localized renal tumors 2,3 . Warm renal ischemia is commonly performed during partial nephrectomy to achieve a bloodless surgical field, however renal ischemia has been associated with renal function impairment 4 .…”

Incidence, clinical evaluation and surgical treatment of patients with renal cell cancer: 40-years of experience in the University Hospital Rijeka

“…Crépel je analizom 5.141 pacijenta pokazao kako je poštedna kirurgija jednako onkološki efikasna kao i radikalna nefrektomija kod pacijenata s KB-om veličine do 7 cm (T1 stadij) 20 . Stoga je i preporuka Europskog urološkog udruženja (EAU) da se u pacijenata s T1 stadijem, ako je tehnički moguće, učini parcijalna nefrektomija 21 . Posebna vrijednost poštedne kirurgije bubrega je maksimalno moguće očuvanje nefronske mase.…”